Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million

Egetis Therapeutics and its subsidiary RTTI agreed to sell their Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 190 million (approximately SEK 1.9 billion). The FDA granted the voucher on September 28, 2026, after approving EMCITATE for MCT8 deficiency. Former RTTI owners are entitled to approximately 50% of net proceeds under an earnout tied to Egetis’ 2020 acquisition of EMCITATE. The sale is subject to customary closing conditions, including expiration of the Hart-Scott-Rodino antitrust waiting period.